@prefix dct: .
@prefix obo: .
@prefix orcid: .
@prefix this: .
@prefix sub: .
@prefix rdfs: .
@prefix xsd: .
@prefix sio: .
@prefix lld: .
@prefix miriam-gene: .
@prefix miriam-pubmed: .
@prefix wi: .
@prefix prov: .
@prefix pav: .
@prefix prv: .
@prefix np: .
@prefix dgn-gda: .
@prefix dgn-void: .
sub:head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:publicationInfo;
a np:Nanopublication .
}
sub:assertion {
dgn-gda:DGNb0b08803467d37fb8f94063fcf38722a sio:SIO_000628 miriam-gene:238, lld:C0007131;
a sio:SIO_001121 .
}
sub:provenance {
sub:assertion dct:description "[The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en;
wi:evidence dgn-void:source_evidence_literature;
sio:SIO_000772 miriam-pubmed:26504000;
prov:wasDerivedFrom dgn-void:BEFREE;
prov:wasGeneratedBy obo:ECO_0000203 .
dgn-void:BEFREE pav:importedOn "2017-02-19"^^xsd:date .
dgn-void:source_evidence_literature a obo:ECO_0000212;
rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en;
rdfs:label "DisGeNET evidence - LITERATURE"@en .
}
sub:publicationInfo {
this: dct:created "2017-10-17T13:10:26+02:00"^^xsd:dateTime;
dct:rights ;
dct:rightsHolder dgn-void:IBIGroup;
dct:subject sio:SIO_000983;
prv:usedData dgn-void:disgenetv3.0rdf;
pav:authoredBy orcid:0000-0001-5999-6269, orcid:0000-0002-7534-7661, orcid:0000-0002-9383-528X,
orcid:0000-0003-0169-8159, orcid:0000-0003-1244-7654;
pav:createdBy orcid:0000-0003-0169-8159;
pav:version "v5.0.0.0" .
dgn-void:disgenetv3.0rdf pav:version "v5.0.0" .
}